Seroprevalence of measles, mumps, rubella, varicella–zoster and hepatitis A–C in Emirati medical students

BMC Public Health

Abdul-Kader Souid⁴  Leena Amiri³  Fatima Al Maskari¹  Ahmed R Alsuwaidi⁴  Rayhan Hashmey²  Mohamud Sheek-Hussein¹ 

[1]Department of Community Medicine, UAE University, College of Medicine and Health Sciences, P.O. Box 17666, Al-Ain, UAE

[2]Department of Infectious Diseases, Tawam Hospital, Al Ain, UAE

[3]Department of Psychiatry, United Arab Emirates University, Al Ain, UAE

[4]Department of Pediatrics, United Arab Emirates University, Al Ain, UAE

关键词: UAE;    Prevention;    Transmission;    Blood borne;    Immunization;    Medical student;   

Others  :  1162761
DOI  :  10.1186/1471-2458-12-1047

 received in 2012-05-21, accepted in 2012-11-27,  发布年份 2012

【 摘 要 】

Background

The aims of this study were to assess the seroprevalence of vaccine-preventable infections in Emirati medical students, and to provide scientific evidence for implementation of a cost-effective immunization guideline and policy for medical school admission.

Methods

This prospective cohort study involved 261 (61% female) Emirati medical students (preclinical and clinical) attending the College of Medicine and Health Sciences at UAE University. Data on vaccination and history of infectious diseases were collected from participants. Blood samples were collected between July 1, 2011 and May 30, 2012 for serological testing and QuantiFERON®-TB assay.

Results

All students tested negative for infection with hepatitis C virus and human immunodeficiency virus. The prevalence of seropositivity to rubella virus was 97%, varicella–zoster virus 88%, mumps virus 84%, measles virus 54%, hepatitis B virus (HBV) 48%, and hepatitis A virus 21%. The QuantiFERON®-TB test was positive in 8% and indeterminate in 2%. Forty percent of students received HBV vaccine at birth; their HBV titers (mean ± SD) were 17.2 ± 62.9 mIU/mL (median = 1.64). The remaining 60% received it at school and their titers were 293.4 ± 371.0 mIU/mL (median = 107.7, p = 0.000).

Conclusion

About 50% of students were susceptible to HBV and measles virus; therefore, pre-matriculation screening for antibodies against these viruses is highly recommended. Moreover, tuberculosis screening is necessary because of the high influx of expatriates from endemic areas. Students with inadequate protection should be reimmunized prior to contact with patients.

【 授权许可】

   
2012 Sheek-Hussein et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Wicker S, Rabenau HF, Gottschalk R, Doerr HW, Allwinn R: Seroprevalence of vaccine preventable and blood transmissible viral infections (measles, mumps, rubella, polio, HBV, HCV and HIV) in medical students. Med Microbiol Immunol 2007, 196(3):145-150.
• [2]Koenig S, Chu J: Medical student exposure to blood and infectious body fluids. Am J Infect Control 1995, 23(1):40-43.
• [3]Norsayani MY, Noor Hassim I: Study on incidence of needle stick injury and factors associated with this problem among medical students. J Occup Health 2003, 45(3):172-178.
• [4]Schmid K, Wallaschofski H, Drexler H: Student health policy of a German medical school–results of a cross sectional study concerning students' immunity to vaccine-preventable diseases. Int J Hyg Environ Health 2004, 207(6):595-600.
• [5]Terada K, Niizuma T, Ogita S, Kataoka N, Niki Y: [Outbreak of measles in a hospital and measures taken against hospital infection–evidence of cost and benefits]. Kansenshogaku Zasshi 2001, 75(6):480-484.
• [6]Torda AJ: Vaccination and screening of medical students: results of a student health initiative. Med J Aust 2008, 189(9):484-486.
• [7]World Health Organization: Immunization Profile - United Arab Emirates. 2012. http://apps.who.int/immunization_monitoring/en/globalsummary/countryprofileselect.cfm webcite
• [8]Baer G, Bonhoeffer J, Schaad UB, Heininger U: Seroprevalence and immunization history of selected vaccine preventable diseases in medical students. Vaccine 2005, 23(16):2016-2020.
• [9]deVries B, Cossart YE: Needlestick injury in medical students. Med J Aust 1994, 160(7):398-400.
• [10]Llewellyn LJ, Harvey I: Hepatitis B vaccination: how many doctors are fully covered? J Public Health Med 1994, 16(3):352-356.
• [11]Dienstag JL, Werner BG, Polk BF, Snydman DR, Craven DE, Platt R, Crumpacker CS, Ouellet-Hellstrom R, Grady GF: Hepatitis B vaccine in health care personnel: safety, immunogenicity, and indicators of efficacy. Ann Intern Med 1984, 101(1):34-40.
• [12]Panizo Delgado A, Martinez Artola V: [Hepatitis B vaccination: immunogenicity of the plasmatic vaccine in hospital personnel]. Med Clin (Barc) 1989, 92(11):401-404.
• [13]Andre F: Hepatitis B epidemiology in Asia, the Middle East and Africa. Vaccine 2000, 18(Suppl 1):S20-22.
• [14]Plotkin S, Orenstein W, Offit P: Vaccines. Philadelphia: Elsevier; 2008.
• [15]Leuridan E, Van Damme P: Hepatitis B and the need for a booster dose. Clin Infect Dis 2011, 53(1):68-75.
• [16]Tufenkeji H: Hepatitis A shifting epidemiology in the Middle East and Africa. Vaccine 2000, 18(Suppl 1):S65-67.
• [17]United Arab Emirates Ministry of Health: Ministry of Health Includes Chicken Pox Vaccine in National Immunization Program. http://www.moh.gov.ae/en/News/Pages/Chicken-Pox-Vaccine.aspx webcite
• [18]Uduman SA, Tahira AM, Al-Wash R, Usmani MA, Bener A: Varicella susceptibility among children and healthy adults in the United Arab Emirates. East Mediterr Health J 2001, 7(4–5):604-608.
• [19]Abro AH, Ustadi AM, Das K, Abdou AM, Hussaini HS, Chandra FS: Chickenpox: presentation and complications in adults. J Pak Med Assoc 2009, 59(12):828-831.